Clinical Trial Update: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of the 20-valent pneumococcal conjugate vaccine in adults 60+ who have not previously received pneumococcal v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2023-11-28